Rivercell Launches With $25 Million to Build Data Platforms and AI Models That Predict How Human Cells Respond to Treatment
Founded by serial entrepreneur and CEO, Yann Fleureau, and former AI research leader at Novartis and Owkin Eric Durand, Rivercell aims to generate high-resolution data on how human cells respond to treatments at scale and train AI models to predict their effects, ultimately accelerating the discovery and development of cures. Seed round led by HV, […]
Rivercell, a Paris-based biotechnology and AI company, has secured a $25 million seed round to develop data platforms and AI models that predict how human cells respond to treatment. The funding, led by HV, will be used to expand Rivercell's proprietary data generation platform, increase its wet lab capabilities in Paris, and launch its AI Virtual Cell program.
The company's world model, which is indication-agnostic, learns the underlying rules of how human cells respond to drugs and genetic changes, making it a potential driver of groundbreaking discoveries across various cell behaviors that lead to disease.
Brief written by urgent.news from Financial Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
